Provider Recommendation and HPV Vaccination

Launched by KAISER PERMANENTE · May 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying ways to improve the rates of HPV vaccination among preteens aged 9 to 12 years old. The research focuses on how healthcare providers can encourage parents to get their children vaccinated against the human papillomavirus (HPV), which can lead to certain cancers. Given that many teens remain unvaccinated despite guidelines recommending the vaccine, this study will compare three different strategies to see which one works best at increasing vaccinations. These strategies include a tailored approach designed with local healthcare teams, a standard approach used by health systems, and the usual care without any special interventions.

Eligible participants for this trial include all pediatric clinics and healthcare providers, such as doctors and nurses, as well as parents of children who are eligible for the HPV vaccine. If you decide to participate, you can expect to be involved in surveys and interviews that gather feedback about the vaccination process. The study aims to see not only if vaccination rates improve but also how effectively providers can recommend the vaccine and the overall cost-effectiveness of the strategies being tested. Your involvement could help make a difference in protecting children from HPV-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All KPSC pediatric clinics.
• • All providers (physicians, nurses, and medical assistants) and department administrators from the pediatric department.
• • Parents of HPV vaccine-eligible children (9-12 years old).
• Exclusion Criteria:
• • Providers and administrators who do not work for the pediatric department
• • Parents of children older than 12 years and/or who did not have a clinic visit in the study period.